Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | DNA2 | P51530 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29583090 | 1.00 | NR4A2 (0.43) | NR4A2ALDH1A1CREBBPDNA2CASP6 | |
| SCHEMBL24704203 | 0.82 | NR4A2 (0.54) | NR4A2ALDH1A1CREBBPMAPTKDM4E | |
| SCHEMBL11322471 | 0.78 | KMT2A (0.48) | ALDH1A1MAPTKMT2AKDM4EMAPK1 | |
| SCHEMBL8416055 | 0.75 | TDP1 (0.58) | ALDH1A1MAPTKMT2AKDM4EMAPK1 | |
| SCHEMBL11359085 | 0.75 | TSHR (0.54) | ALDH1A1DNA2CASP6CTDSP1MAPT | |
| SCHEMBL30033568 | 0.74 | ALDH1A1 (0.50) | ALDH1A1DNA2CASP6CTDSP1MAPT | |
| SCHEMBL2843773 | 0.72 | NR4A2 (0.62) | NR4A2ALDH1A1CREBBPMAPTKMT2A | |
| SCHEMBL9080086 | 0.72 | KMT2A (0.46) | ALDH1A1MAPTKMT2AKDM4EMAPK1 | |
| SCHEMBL29959661 | 0.71 | TSHR (0.70) | ALDH1A1MAPTKMT2AKDM4EMAPK1 | |
| SCHEMBL307312 | 0.71 | TSHR (0.70) | ALDH1A1MAPTKMT2AKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116457339-A | Tricyclic compounds degrading novel substrates for medical treatment | C4医药公司 | 2023-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | NR4A2 1299/4885ALDH1A1 4099/4885CREBBP 802/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | NR4A2 649/4885ALDH1A1 2267/4885CREBBP 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.